- Conditions
- Lung Cancer, Cancer of the Lung
- Interventions
- Pink and Pearl Campaign
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 20 Years and older
- Enrollment
- 5,515 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2521–2544
of 4,500
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancers, Gastrointestinal Cancers
- Interventions
- Priming Survey
- Behavioral
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Mesothelioma, Malignant
- Interventions
- Placebo, Amatuximab, Pemetrexed, Cisplatin
- Drug
- Lead sponsor
- Morphotek
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 7
- States / cities
- La Jolla, California • Newark, Delaware • Bethesda, Maryland + 4 more
- Conditions
- Brenner Tumor, Malignant Ascites, Malignant Pleural Effusion, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Epithelial Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Undifferentiated Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Epithelial Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cavity Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Epithelial Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cavity Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Epithelial Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cavity Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cavity Cancer
- Interventions
- metformin hydrochloride, placebo, Chemotherapy
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Duarte, California + 6 more
- Conditions
- Colorectal Cancer; Lung Cancer
- Interventions
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Drug
- Lead sponsor
- Teclison Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Lung Carcinoma, Tobacco-Related Carcinoma
- Interventions
- Biospecimen Collection, Nutritional Supplementation, Placebo Administration, Questionnaire Administration
- Procedure · Dietary Supplement · Drug + 1 more
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 55 Years to 77 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Sacituzumab Govitecan-hziy (SG), Pembrolizumab, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 22
- States / cities
- Anchorage, Alaska • Beverly Hills, California • Los Angeles, California + 17 more
- Conditions
- Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- Pembrolizumab
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Lung Carcinoma, Metastatic Lung Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Best Practice, Questionnaire Administration
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Extensive-Stage Small Cell Lung Cancer
- Interventions
- BMS-986489 (Atigotatug+Nivolumab), Atezolizumab, Carboplatin, Etoposide
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 20
- States / cities
- Daphne, Alabama • Hot Springs, Arkansas • Fort Myers, Florida + 17 more
- Conditions
- Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
- Interventions
- Binimetinib Pill, Hydroxychloroquine Pill
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma, Gastroesophageal Junction Adenocarcinoma
- Interventions
- PF-08098488
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Grand Rapids, Michigan • Nashville, Tennessee • San Antonio, Texas
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Imprime PGG, MK-3475
- Drug
- Lead sponsor
- Lawrence Feldman, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Iowa City, Iowa + 2 more
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
- Interventions
- HBI-2438
- Drug
- Lead sponsor
- HUYABIO International, LLC.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 13
- States / cities
- Encinitas, California • Glendale, California • Long Beach, California + 9 more
- Conditions
- Lung Cancer
- Interventions
- Gemcitabine, Carboplatin, Paclitaxel, Radiation
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Esophageal Squamous Cell Carcinoma (ESCC)
- Interventions
- Tumor-Informed ctDNA Assessment (Signatera™ Genome Assay)
- Diagnostic Test
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7, PD-L1 Gene Mutation, Advanced Treatment-Naïve PD-L1, Sitravatinib, Pembrolizumab
- Interventions
- Sitravatinib, Pembrolizumab
- Drug
- Lead sponsor
- Sarah Goldberg
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Lung Cancer
- Interventions
- cisplatin, docetaxel, adjuvant therapy
- Drug · Procedure
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • New York, New York • Nashville, Tennessee
- Conditions
- Head and Neck Cancer, Lung Cancer, Lymphoma
- Interventions
- Amifostine administered subcutaneously
- Drug
- Lead sponsor
- Mt. Sinai Medical Center, Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Miami Beach, Florida
- Conditions
- Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Chemotherapy, Pembrolizumab, Ramucirumab
- Drug · Biological
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 838 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 566
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more
- Conditions
- Carcinoma, Midline
- Interventions
- GSK525762
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- Thoracic Tumors, Non-small Cell Lung Cancer
- Interventions
- Anvumetostat, Carboplatin, Paclitaxel, Pembrolizumab, Pemetrexed, Sotorasib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 26
- States / cities
- Bakersfield, California • Duarte, California • Los Angeles, California + 20 more
- Conditions
- Lung Cancer
- Interventions
- celecoxib, Docetaxel, pemetrexed disodium, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 3
- States / cities
- Nashville, Tennessee
- Conditions
- Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Interventions
- therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT), quality-of-life assessment
- Combination Product · Other
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Buffalo, New York